PHARMECO Advancing SSbD Practices in Pharmaceutical Manufacturing

The pharma sector has a significant impact on the environment; in terms of CO₂ emissions, use of water, energy, solvents and fossil-based raw materials, as well as generation of a lot of waste.

By implementing cutting-edge technologies and methodologies across different manufacturing stages, the project strategically targets critical environmental concerns like the reduction/elimination of solvents and substitution of toxic chemicals and reagents, while advancing resource efficiency, operational sustainability, and eco-friendly production methodologies.  

PHARMECO will also harmonise the way sustainability assessments of pharmaceuticals are carried out, by delivering guidelines that are scientifically-robust, practical, and accepted by all stakeholders.

PHARMECO will address the production of small molecules, tides, and biologics, medical devices & technologies, with a key focus on: Safe and Sustainable-by-Design (SSbD) platforms for early-stage pharmaceutical development. Green processes for industrial-scale manufacturing and decontamination. Advanced digital tools for sustainability assessment and decision-making.

Together, the project outputs will form a comprehensive toolkit to support the development and manufacture of more sustainable pharmaceuticals and to evaluate their environmental impact along the whole life cycle.

This project is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No 101165889. The JU receives support from the European Union’s Horizon Europe research and innovation programme and COCIR, EFPIA, Europa Bío, MedTech Europe, and Vaccines Europe.

Disclaimer : Funded by the European Union and the private members of the IHI JU.
Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the aforementioned parties. Neither of the aforementioned parties can be held responsible for them.